Receptor activator of nuclear factor kappa-B ligand induces osteoclast precursor culture and differentiation

doi:10.3969/j.issn.2095-4344.2013.46.001

Abstract

Abstract:

BACKGROUND: Previous studies have applied long-bone mechanical separation method to obtain osteoclasts, which are terminally differentiated cells and cannot further proliferate. Therefore a large number of osteoclasts can be harvested with bone marrow cells inducing culture method and RAW264.7 cells inducing culture method to meet clinical requirements.
OBJECTIVE: To investigate the optimal method of receptor activator of nuclear factor kappa-B ligand (RANKL) induced osteoclast precursors to differentiate into mature osteoclasts.
METHODS: After bone marrow cells were isolated from mouse, RANKL and macrophage colony stimulating factor were added into the medium together, or RAW264.7 cells were cultured with RANKL to induce osteoclasts. The osteoclast precursors were treated with different concentrations of RANKL to observe the number of generated osteoclasts and evaluate the dose-effect relationship between RANKL and osteoclastogenesis. Annexin V-FITC and propidium iodide staining were used for flow cytometry to analyze the mononuclear-macrophage apoptosis during osteoclastogenesis.
RESULTS AND CONCLUSION: When 10 μg/L RANKL was used, the peak of osteoclastogenesis appeared at days 6-7; when the concentration of RANKL was up to 100 μg/L, the peak appeared at days 4-5. The number of new osteoclasts was dose-dependent on the RANKL concentration. 50 μg/L of RANKL was the turning point in the fitted curve from osteoclastogenesis and RANKL concentration. After the RANKL concentration was more than 150 μg/L, the number of osteoclasts slowed down obviously. RANKL can induce monocyte-macrophage to form osteoclasts and promote monocyte-macrophage apoptosis. The highest number of osteoclasts would be obtained to each unit of RANKL when monocyte-macrophage cells were cultured with 30 μg/L of RANKL in the same vaccination density (104/cm²). Experimental findings indicate that, RAW264.7 cells or bone marrow cells inducing culture methods are simple and feasible, the optimum cell seeding density was 104/cm²; the appropriate stimulation concentration of RANKL was 30-50 μg/L.

Key words: RANKL, osteoclasts, apoptosis, mononuclear phagocyte system, bone marrow cells

CLC Number:

R318

Zhu Wei-ping, Shi Wei, Lin Lin, Li Zhong-he, Huang Jin. Receptor activator of nuclear factor kappa-B ligand induces osteoclast precursor culture and differentiation[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(46): 7981-7987.

Figures/Tables 5

References

[1]Horowitz MC, Xi Y, Wilson K, et al. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev. 2001;12(1):9-18.

[2]Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A.1990;87(18): 7260-7264.

[3]刘波,于世凤,庞淑珍.新伐他汀体外对破骨细胞性骨吸收及大鼠骨代谢的影响[J].中国骨质疏松杂志,2005,11(3): 351-355.

[4]邱君思,陈靖. 无动力型骨病发病机制的新进展[J].中国血液净化,2007,6(11):614-617.

[5]邢联平,张倩,姚振强. 破骨细胞介导炎症性骨丢失的研究进展[J].中华创伤骨科杂志,2006,8(7):671-674.

[6]胡永成,王志强,孙世荃,等. 同种异体骨移植后的病理组织学观察[J].中华骨科杂志,2004,24(10):597-603.

[7]Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab. 2012;23(11):582-590.

[8]Hughes A, Kleine-Albers J, Helfrich MH, et al. A class III semaphorin (Sema3e) inhibits mouse osteoblast migration and decreases osteoclast formation in vitro. Calcif Tissue Int. 2012;90(2):151-162.

[9]Zheng K, Chen DS, Wu YQ, et al. MicroRNA expression profile in RAW264.7 cells in response to Brucella melitensis infection. Int J Biol Sci. 2012;8(7):1013-1022.

[10]张庆鸿,梁星,刘梦桃. 体外培养鼠破骨细胞对牙体硬组织的吸收实验[J]. 口腔医学,2007,27(9):452-454.

[11]朱振康,骆峪潇,李陶冶,等.破骨细胞体外培养的影响因素[J]. 浙江临床医学,2011,13(5):559-562.

[12]许多荣,余学清,方荸荠.甲状旁腺激素在体外对破骨细胞分化及骨重吸收能力的影响[J].中华肾脏病杂志,2005,21(4):186-190.

[13]Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res. 2000;15(8): 1477-1488.

[14]Dempster DW, Hughes-Begos CE, Plavetic-Chee K, et al. Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem. 2005; 95(1):139-148.

[15]戴闽,程明,张斌,等. RAW264.7细胞在体外分化成破骨细胞的研究[J]. 天津医药,2010, 38(7):596-598.

[16]肖新华,周后德,王运林,等. RANKL诱导小鼠单核细胞RAW264.7分化成成熟破骨细胞[J]. 中国骨质疏松杂志,2005, 11(2):151-155.

[17]Rahman MM, Bhattacharya A, Fernandes G. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling. J Lipid Res. 2006;47(8):1739-1748.

[18]Kudo O, Sabokbar A, Pocock A, et al. Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts. Calcif Tissue Int. 2002;71(6):539-546.

[19]Mochizuki A, Takami M, Miyamoto Y, et al. Cell adhesion signaling regulates RANK expression in osteoclast precursors. PLoS One. 2012;7(11):e48795.

[20]Xu D, Shi Z, Mcdonald J, et al. Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members. Biochem J. 2004;383(Pt 2): 219-225.

[21]Liu Y, Song L, Wang Y, et al. Osteoclast differentiation and function in aquaglyceroporin AQP9-null mice. Biol Cell. 2009; 101(3):133-140.

[22]毛英杰,谷志远,赵鹃.不同细胞接种密度及饥饿对RAW264.7诱导分化的影响[J].中国口腔种植学杂志,2009,14(2):124-125.

[23]Tomomura M, Hasegawa H, Suda N, et al. Serum calcium-decreasing factor, caldecrin, inhibits receptor activator of NF-kappaB ligand (RANKL)-mediated Ca2+ signaling and actin ring formation in mature osteoclasts via suppression of Src signaling pathway. J Biol Chem. 2012;287 (22):17963-17974.

[24]Ikeda F, Matsubara T, Tsurukai T, et al. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts. J Bone Miner Res. 2008;23(6):907-914.

[25]Wu SH, Zhong ZM, Chen JT. Low-magnitude high-frequency vibration inhibits RANKL-induced osteoclast differentiation of RAW264.7 cells. Int J Med Sci. 2012;9(9):801-807.

[26]Hodge JM, Collier FM, Pavlos NJ, et al. M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One. 2011;6(6):e21462.

[27]Makihira S, Mine Y, Kosaka E, et al. Titanium surface roughness accelerates RANKL-dependent differentiation in the osteoclast precursor cell line, RAW264.7. Dent Mater J. 2007;26(5):739-745.

[28]董伟,于静,戚孟春,等. M-CSF、RANKL浓度及M-CSF预诱导对破骨细胞生成影响的研究[J]. 生物医学工程学杂志,2010, 27(6): 1336-1340.

[29]包洪卫,孙继芾,王青. 巨噬细胞集落刺激因子/核因子κB受体激活物配体体外诱导培养高纯度破骨细胞：最佳剂量探讨[J]. 中国组织工程研究与临床康复,2010,14(2):191-195.

[30]Raju R, Balakrishnan L, Nanjappa V, et al. A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway. Database (Oxford).2011;2011:r21.

[31]周怡,刘丽,张庆鸿. 鼠破骨细胞培养过程中凋亡现象的观察研究[J]. 口腔医学,2010, 30(2):90-92.

[32]Lamothe B, Lai Y, Xie M, et al. TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis. Mol Cell Biol. 2013;33(3):582-595.

[33]Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol. 2010;22(2): 263-268.

[34]Bharti AC, Aggarwal BB. Ranking the role of RANK ligand in apoptosis. Apoptosis. 2004;9(6):677-690.

[35]Sugatani T, Hruska KA. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem. 2005; 280(5):3583-3589.

[36]Glantschnig H, Fisher JE, Wesolowski G, et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003; 10(10):1165-1177.

[37]Sankar U, Patel K, Rosol TJ, et al. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1. J Bone Miner Res. 2004;19(8):1339-1348.

[38]Lutter AH, Hempel U, Wolf-Brandstetter C, et al. A novel resorption assay for osteoclast functionality based on an osteoblast-derived native extracellular matrix. J Cell Biochem. 2010;109(5):1025-1032.

[39]Okui T, Shimo T, Fukazawa T, et al. Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction. Mol Cancer Ther. 2010; 9(11):2960-2969.

[40]Tang CH, Hsu TL, Lin WW, et al. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J Biol Chem. 2007;282(4):2346-2354.